Low-dose Erythropoietin reduces risk of heart failure induced by anti-cancer therapy
Oncotarget
.
2011 Nov;2(11):825.
doi: 10.18632/oncotarget.352.
Authors
Melanie Hoch
,
Denise Hilfiker-Kleiner
PMID:
22084151
PMCID:
PMC3259998
DOI:
10.18632/oncotarget.352
No abstract available
Publication types
Editorial
MeSH terms
Animals
Antineoplastic Agents / adverse effects*
Erythropoietin / pharmacology*
Heart Failure / chemically induced*
Heart Failure / prevention & control*
Humans
Risk
Substances
Antineoplastic Agents
Erythropoietin